What is pathophysiology of Prostate cancer?

['Ivwilila ku chihanda chino']

Yika yakuneha yikola ya kansa ya prostate?

Pathophysiology ya cancer ya prostate yinalumbunuka yuma yize yakuneha yikola yacho.

Cikola cha kansa ya prostate yili yikola yize yakukwata atu waze ali ni kansa yacho.

Prostate gland yakukasa yikola ya seminal, yize yakukwasa ni kuyendesa ayo.

Chuma cheji kulingisanga musongo wa kansa kuchinyingike kanawa, alioze kuli yuma yinji yize yakuneha musongo wacho.

Chino chili ngwe miaka, usoko, vungu ni kwalumuka cha shinga.

Musongo wa prostate unji ku malunga waze ali ni miaka yinji, unji wa atu waze akuyiza ni kansa wacho kali waze ali ni miaka 65 ni kuhiana.

Nawa malunga waze asoko jo kakwete yikola yacho, kali mu ponde.

Musongo wa cancer ya prostate unatale ha kukola ni kulihandununa cha ma celula mu prostate gland.

Chino muchihasa kulingiwa ha mukunda wa kwalumuka cha shinga chize chakuneha kukola cha yuma yize yakukolesa hanji kukoka cha ma genes.

Chino muchihasa kulingisa maselusi kukola chakuhona kulita ni chize chinatela kupwa ni tumor.

Muze tumor yakula, muyihasa kuputuka kuyijiha yihanda yize yili hakamwihi, ngwe musongo wa chisuji, hanji haze hakutuhuka mujimo.

Ha mashimbu amwe, ma celula a cancer mahasa kuputuka ku tumor yitangu ni kuhanda ni kulianga mu yihanda yikwo ya mujimba ha kupalika cha manyinga hanji ha sistema ya lymphatic, chino kakuchinyingika ngwo metastasis.

Muze yikola yacho muyiza, muchipwa chikalu kuyiwuka.

Musongo wa prostate mahasa kupinjisa nawa kuli yuma yize yakuneha yihemba, chikumanyi hormone testosterone.

Testosterone yakukwasa hanga ma celula a cancer a prostate akole chinji, nawa yikumba yinji yize akuzachisa hanga akuhwise kansa yacho yakukwasa hanga akeheseko hormone yacho hanji ahone kuyikoka.

Ha chino, uhashi wa cancer ya prostate unatale ha kukola ni kulihandununa cha ma celula mu prostate gland, chino muchihasa kupwa ni yikola ya mu citumbo, ya mu mijimba ni ya mu chifuchi.

Kunyingika kanawa yize yakuneha yikola yacho chili chilemu chinji hanga atu ahase kuchiza kanawa yikola yacho ni kuhwisa yikola yacho.

['Kuhanjika']

PubMed/Medline https://www.nlm.nih.gov/databases/download/pubmed_medline.html

RefinedWeb https://arxiv.org/abs/2306.01116

Zobniw CM, Causebrook A, Fong MK: Clinical use of abiraterone in the treatment of metastatic castration-resistant prostate cancer. Res Rep Urol. 2014, 6 (): 97-105.

Lim HY, Agarwal AM, Agarwal N, Ward JH: Recurrent epistaxis as a presenting sign of androgen-sensitive metastatic prostate cancer. Singapore Med J. 2009, 50 (5): e178-80.

Kohli M, Qin R, Jimenez R, Dehm SM: Biomarker-based targeting of the androgen-androgen receptor axis in advanced prostate cancer. Adv Urol. 2012, 2012 (): 781459.

Nelson JB, Hedican SP, George DJ, Reddi AH, Piantadosi S, Eisenberger MA, Simons JW: Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nat Med. 1995, 1 (9): 944-9.

Msaouel P, Nandikolla G, Pneumaticos SG, Koutsilieris M: Bone microenvironment-targeted manipulations for the treatment of osteoblastic metastasis in castration-resistant prostate cancer. Expert Opin Investig Drugs. 2013, 22 (11): 1385-400.

Kotani K, Sekine Y, Ishikawa S, Ikpot IZ, Suzuki K, Remaley AT: High-density lipoprotein and prostate cancer: an overview. J Epidemiol. 2013, 23 (5): 313-9.

Jadvar H: Molecular imaging of prostate cancer: a concise synopsis. Mol Imaging. , 8 (2): 56-64.

['Ulemu: ukwaso wa yikola']

['Site yino kayitela hanga atu anyingike hakutwala ku yikola ni yikuma yikwo, kuyishi ni yiyulo ya mandotolo.']

['Sango jacho katambile kujizachisa hanga awane hanji awahise yikola, nawa waze anafupu yiyulo ya mandotolo katamba kuya kuli ndotolo.']

['Tala ha makina yize yakukwasa hanga uwane kumbululo lia yihula, hi yikalu ko muze anavuluka unji wa atu waze ali ni yikola.']

['Teta mashimbu eswe kuwana yiyulo ya ndotolo we hanji umwe mukwa-kuhana yiyulo ya uhayele ha chikuma cha yikola. Kanda ulionga yiyulo ya ndotolo hanji kutohwesa kuyitanga ha mukunda wa yimwe yuma yize watanga ha site yino. Nyi wanyonga ngwo uli ni mulonga wa uhayele, shinga 911 hanji yako ha chipatulo cha usopeso chize chili hakamwihi. Kukushi usepa wa ndotolo ni ndotolo uze wakunjila ha site yino hanji ha kuzachisa site yino. Chipwe BioMedLib hanji akwa-kukalakala nayo, hanji yoze wakukwasa ha site yino, keshi kulinga nichimwe, chipwe kusolola, hakutwala ku sango jize jili ha site yino hanji ha kuzachisa site yino.']

['Uhashi wa akwa-kusoneka']

['Shimbi ya Digital Millennium Copyright Act ya 1998, 17 U.S.C. § 512 (DMCA) yinambe ngwo, waze ali ni shimbi ja akwa-kusoneka waze anafuliela ngwo yuma yize yili ha Internet yinapinjisa shimbi ja akwa-kusoneka ja mu Estados Unidos. ']

['Nyi unafuliela ni mbunge yeswe ngwo yikuma yeswe yize akuzachisa ha site yino yinapinjisa shimbi ja akwa-kusoneka, yena (mba yoze wakuzachisa) muhasa kututumina mukanda hanga ututuhwise yikuma yacho hanji kuhona kuyimona.']

['Sango jacho katamba kujituma ha mukanda ha email (tala ha chihanda cha "Contact" ha email).']

['Shimbi ya DMCA yinambe ngwo, sango je ha yize akuhanjika ngwo yapinjisa shimbi ja akwa-kusoneka yili ni sango jacho: (1) kulumbununa mulimo uze uli ni shimbi ja akwa-kusoneka uze anazangamisa; (2) kulumbununa yikuma yize anazangamisa ni sango jize jinahase kutukwasa hanga tuwane yikuma yacho; (3) kulweza yoze mutuhasa kumuheta, ngwe adresi, numero ya telefone ni email; (4) maliji waze yena musolola ngwo, yuma yize anazangamisa kuyishi ni utayizo wa mwene wa shimbi ja akwa-kusoneka, hanji yoze akuzachisa, hanji ni shimbi jize anazangamisa; ']

['(5) Sango jize yena musoneka, ni shimbi jize makahana, ngwo sango jize jili ha mukanda jili ja umwenemwene nawa uli ni ulite wakukwasa hanga akwa-kusoneka afunge shimbi jize anakwambulula ngwo jinalitepulula;']

['nawa (6) chijimbikilo cha mwata wa shindakenyo ya ulite wa yuma hanji cha muthu yoze uli ni ulite wa kulinga yuma ha jina lia mwata wa shindakenyo ya yuma.']

['Nyi kuhona kusa sango jacho mu mukanda, kuchihasa kutohwesa chikuma chikuma.']

['Kulitakana']

['Tutuminenu mukanda ni yihula ni yiyulo yenu.']

What is pathophysiology of prostate cancer?

The pathophysiology of prostate cancer refers to the underlying mechanisms and processes that lead to the development and progression of the disease.

Prostate cancer is a malignant tumor that arises from the cells of the prostate gland, which is a small, walnut-shaped organ located below the bladder in men.

The prostate gland produces seminal fluid, which nourishes and transports sperm.

The exact cause of prostate cancer is not fully understood, but several factors are known to increase the risk of developing the disease.

These include age, family history, race, and certain genetic mutations.

Prostate cancer is more common in older men, with the majority of cases occurring in men over the age of 65.

Additionally, men with a family history of prostate cancer are at an increased risk, as are African American men and men of Caribbean descent.

The pathophysiology of prostate cancer involves the uncontrolled growth and division of cells within the prostate gland.

This can occur due to genetic mutations that lead to the overexpression of certain growth factors or the inactivation of tumor suppressor genes.

These mutations can result in the unregulated growth of cells, leading to the formation of a tumor.

As the tumor grows, it can invade nearby tissues and organs, such as the bladder, rectum, and nearby lymph nodes.

In some cases, cancer cells can break away from the primary tumor and spread to other parts of the body through the bloodstream or lymphatic system, a process known as metastasis.

Once the cancer has spread, it can be more difficult to treat.

Prostate cancer can also be influenced by hormonal factors, particularly the androgen hormone testosterone.

Testosterone can stimulate the growth of prostate cancer cells, and many treatments for prostate cancer aim to reduce the levels of this hormone or block its effects.

In summary, the pathophysiology of prostate cancer involves the uncontrolled growth and division of cells within the prostate gland, which can be influenced by genetic, hormonal, and environmental factors.

Understanding the underlying mechanisms of the disease is crucial for developing effective treatments and improving outcomes for patients with prostate cancer.

Disclaimer: medical

This web site is provided for educational and informational purposes only and does not constitute providing medical advice or professional services.

The information provided should not be used for diagnosing or treating a health problem or disease, and those seeking personal medical advice should consult with a licensed physician.

Please note the neural net that generates answers to the questions, is specially inaccurate when it comes to numeric content. For example, the number of people diagnosed with a specific disease.

Always seek the advice of your doctor or other qualified health provider regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. If you think you may have a medical emergency, call 911 or go to the nearest emergency room immediately. No physician-patient relationship is created by this web site or its use. Neither BioMedLib nor its employees, nor any contributor to this web site, makes any representations, express or implied, with respect to the information provided herein or to its use.

Disclaimer: copyright

The Digital Millennium Copyright Act of 1998, 17 U.S.C. § 512 (the “DMCA”) provides recourse for copyright owners who believe that material appearing on the Internet infringes their rights under U.S. copyright law. If you believe in good faith that any content or material made available in connection with our website or services infringes your copyright, you (or your agent) may send us a notice requesting that the content or material be removed, or access to it blocked. Notices must be sent in writing by email (see 'Contact' section for email address) . The DMCA requires that your notice of alleged copyright infringement include the following information: (1) description of the copyrighted work that is the subject of claimed infringement; (2) description of the alleged infringing content and information sufficient to permit us to locate the content; (3) contact information for you, including your address, telephone number and email address; (4) a statement by you that you have a good faith belief that the content in the manner complained of is not authorized by the copyright owner, or its agent, or by the operation of any law; (5) a statement by you, signed under penalty of perjury, that the information in the notification is accurate and that you have the authority to enforce the copyrights that are claimed to be infringed; and (6) a physical or electronic signature of the copyright owner or a person authorized to act on the copyright owner’s behalf. Failure to include all of the above information may result in the delay of the processing of your complaint.